Welcome to our dedicated page for Immucell SEC filings (Ticker: ICCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImmuCell filings document material events and governance matters for an animal health biologics company built around First Defense. Form 8-K reports record preliminary and annual financial results, board retirements and appointments, senior-officer employment agreements, and settlement of claims tied to a prior development services and commercial supply agreement.
Definitive proxy materials cover director matters, board oversight, executive compensation, and equity-award disclosures. The filing record also includes exhibits with company press releases addressing product sales, financial condition, strategic focus, and related operating updates.
ImmuCell Corporation filed a Form 4 for Chief Financial Officer and director Timothy C. Fiori reporting a new stock option grant. On January 27, 2026, he received 120,000 stock options with an exercise price of $6.265 per share, held directly.
The option is intended to qualify as an incentive stock option to the maximum extent allowed under the Internal Revenue Code, with the remainder as a nonqualified option. It vests in three equal tranches of 40,000 options on each of the first, second, and third anniversaries of the grant date.
ImmuCell Corporation filed a Form 4 showing an option grant to executive and director Bobbi Jo Brockmann. On January 27, 2026, she received stock options to purchase 100,000 shares of common stock at an exercise price of $6.265 per share, expiring on January 27, 2036.
The options were granted in connection with her role as Vice President of Sales and Marketing. They vest over three years: 33,333 shares become exercisable on each of January 27, 2027 and January 27, 2028, and 33,334 shares become exercisable on January 27, 2029. Following this grant, she beneficially owns 100,000 derivative securities directly.
Immucell Corporation reported a new equity award to its President and CEO, Paul Francis Olivier te Boekhorst. On January 27, 2026, he was granted 110,000 stock options with an exercise price of $6.265 per share.
The option is intended to qualify as an incentive stock option to the maximum extent allowed, with any remainder treated as a nonqualified option. All of the options will vest only if Immucell’s net operating income for four consecutive calendar quarters reaches at least 300% of its audited net operating income for the 2025 fiscal year.
ImmuCell Corporation reported that it has released preliminary, unaudited sales results for the three‑month and twelve‑month periods ended December 31, 2025, via a January 8, 2026 press release. The company also disclosed that it will record approximately $3.6 million in non‑cash impairment write‑downs for the quarter ended December 31, 2025, and stated it does not expect these charges to lead to material future cash expenditures, although actual amounts may differ from current estimates.
The company highlighted a strategic shift toward its First Defense® product line and away from Re‑Tain®, and scheduled a conference call on January 9, 2026 to discuss top‑line results and this shift. A second conference call is planned for February 26, 2026 to review full, unaudited financial results for the quarter and year ended December 31, 2025, which the company expects to release after market close on February 25, 2026.
ImmuCell Corporation (ICCC) reported Q3 2025 results. Product sales were $5,506,122 versus $6,011,573 a year ago, and the quarter showed a net loss of $139,748 compared with a loss of $701,690 last year. Gross margin improved to $2,363,098 from $1,583,554 as costs of goods sold declined.
For the nine months ended September 30, 2025, product sales reached $20,018,175 versus $18,742,040, and net income was $1,809,115 versus a loss of $2,671,184 last year. Cash and cash equivalents were $3,886,198. Inventory stood at $9,802,005. Total liabilities were $15,929,282 and stockholders’ equity was $29,800,841.
Capital and financing: During Q3 2025, the company refinanced prior loans into a new $2,327,119 MCB term loan at a fixed 6.5% rate, replacing 7% and 8% debt, removing July 2026 balloon payments and setting monthly payments of $45,637 through the third quarter of 2030.
Concentration: Two customers represented 68% of Q3 product sales. Shares outstanding were 9,045,851 as of October 31, 2025.
ImmuCell Corporation furnished an 8-K announcing it issued a press release with unaudited financial results for the quarter ended September 30, 2025. The disclosure is under Item 2.02 and is expressly stated as furnished, not filed, which limits liability under Section 18.
The filing includes Exhibit 99.1 (press release dated November 13, 2025) and Exhibit 104 (cover page Inline XBRL).
ImmuCell Corp (ICCC) reported a Form 4 showing its President and CEO (also a Director) received a grant of 74,277 stock options at an exercise price of $6.10 on November 7, 2025.
The options vest in three equal tranches of 24,759 on the first, second, and third anniversaries of the grant and expire on November 7, 2035. The award will be treated as an incentive stock option to the maximum extent permitted, with the balance as a nonqualified option. Following the grant, the officer beneficially owned 150,260 derivative securities.
ImmuCell (ICCC) filed a Form 3 reporting initial beneficial ownership for its President and CEO. The filing lists three nonqualified stock options to purchase Common Stock at an exercise price of $5.90 per share, covering 25,327, 25,327, and 25,329 shares. These options become exercisable on 09/16/2026, 09/16/2027, and 09/16/2028, respectively, and each expires on 09/16/2035. The grant was made in connection with an offer letter outlining the terms of his employment and vests in three increments as shown.
ImmuCell Corporation announced governance changes tied to its CEO transition. Effective November 1, 2025, Olivier te Boekhorst became President and CEO, while Michael F. Brigham stepped down from his roles as President, CEO, Secretary, and Treasurer to serve as Special Advisor to the CEO. On October 29, 2025, the Board expanded from seven to nine directors and elected Mr. te Boekhorst and CFO Timothy C. Fiori as directors. Mr. Fiori was also elected Secretary and Treasurer. Neither executive was appointed to any Board committees.
ImmuCell Corporation filed a current report to let investors know it has released preliminary, unaudited product sales figures for the quarter ended September 30, 2025. The company communicated these early sales results through a press release dated October 7, 2025, which is included as Exhibit 99.1 to the report. The exhibit is designated as “furnished” rather than “filed,” meaning it is provided for information purposes under securities rules without being incorporated into other filings unless specifically referenced.